Skip to main content
AKTS
NASDAQ Life Sciences

10% Owner Vida Ventures Makes Substantial $123.6M Investment in Aktis Oncology

KI-Analyse von Wiseek
Stimmung info
Positiv
Wichtigkeit info
8
Preis
$21.75
Marktkapitalisierung
$1.142B
52W Tief
$19.333
52W Hoch
$29.16
Market data snapshot near publication time

summarizeZusammenfassung

This Form 4 filing indicates a strong vote of confidence from Vida Ventures II, a major institutional investor and 10% owner. The substantial investment, comprising both direct open market purchases and conversions of preferred stock into common stock, represents a significant portion of Aktis Oncology's market capitalization. Such a large capital commitment from a key investor suggests a positive outlook on the company's future prospects and could be interpreted by the market as a bullish signal.


check_boxSchlusselereignisse

  • Significant Capital Commitment

    Vida Ventures II, a 10% owner, increased its stake in Aktis Oncology through transactions valued at $123.6 million.

  • Open Market Purchases

    The investment included $15.03 million in direct open market purchases of common stock at $18.00 per share.

  • Preferred Stock Conversions

    The remaining portion of the investment involved the conversion of preferred stock into 4,994,212 shares of common stock.


auto_awesomeAnalyse

This Form 4 filing indicates a strong vote of confidence from Vida Ventures II, a major institutional investor and 10% owner. The substantial investment, comprising both direct open market purchases and conversions of preferred stock into common stock, represents a significant portion of Aktis Oncology's market capitalization. Such a large capital commitment from a key investor suggests a positive outlook on the company's future prospects and could be interpreted by the market as a bullish signal.

Zum Zeitpunkt dieser Einreichung wurde AKTS bei 21,75 $ gehandelt an der NASDAQ im Sektor Life Sciences, bei einer Marktkapitalisierung von rund 1,1 Mrd. $. Die 52-Wochen-Handelsspanne lag zwischen 19,33 $ und 29,16 $. Diese Einreichung wurde mit positiver Marktstimmung und einem Wichtigkeitsscore von 8 von 10 bewertet.

descriptionHaupt-SEC-Einreichung ansehen

show_chartPreisdiagramm

Diesen Artikel teilen

Copied!

feed AKTS - Neueste Einblicke

AKTS
Apr 16, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
AKTS
Mar 30, 2026, 5:29 PM EDT
Filing Type: 10-K
Importance Score:
8
AKTS
Mar 30, 2026, 4:45 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
AKTS
Jan 20, 2026, 5:44 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
8
AKTS
Jan 20, 2026, 2:01 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
8
AKTS
Jan 15, 2026, 6:02 AM EST
Filing Type: SCHEDULE 13D
Importance Score:
9
AKTS
Jan 14, 2026, 6:20 PM EST
Filing Type: 4
Importance Score:
8
AKTS
Jan 14, 2026, 6:19 PM EST
Filing Type: 4
Importance Score:
7
AKTS
Jan 14, 2026, 6:17 PM EST
Filing Type: 4
Importance Score:
7
AKTS
Jan 14, 2026, 4:58 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
8